Changes in plasma IL-6, plasma VEGF and serum YKL-40 during Treatment with Etanercept and Methotrexate or Etanercept alone in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy

Lene Surland Knudsen; Merete Lund Hetland; Julia Sidenius Johansen; Henrik Skjødt; Niels Daugaard Peters; Ada Colic; Karin Grau; Hans Jørgen Nielsen; Mikkel Østergaard; Lene Surland Knudsen; Merete Lund Hetland; Julia Sidenius Johansen; Henrik Skjødt; Niels Daugaard Peters; Ada Colic; Karin Grau; Hans Jørgen Nielsen; Mikkel Ostergaard

Changes in plasma IL-6, plasma VEGF and serum YKL-40 during Treatment with Etanercept and Methotrexate or Etanercept alone in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy

Lene Surland Knudsen, Merete Lund Hetland, Julia Sidenius Johansen, Henrik Skjødt, Niels Daugaard Peters, Ada Colic, Karin Grau, Hans Jørgen Nielsen, Mikkel Østergaard, Lene Surland Knudsen, Merete Lund Hetland, Julia Sidenius Johansen, Henrik Skjødt, Niels Daugaard Peters, Ada Colic, Karin Grau, Hans Jørgen Nielsen, Mikkel Ostergaard

Abstract

Changes in plasma IL-6, plasma VEGF and serum YKL-40 were determined in rheumatoid arthritis (RA) patients during treatment with etanercept alone or in combination with methotrexate. Twenty-five patients with active RA (DAS28 >/= 3.2) were randomized to receive etanercept (25 mg sc. biweekly) plus methotrexate (n = 12) or etanercept alone (n = 13). Plasma IL-6, plasma VEGF and serum YKL-40 were determined by ELISA. The 3 biomarkers and DAS28 scores were evaluated at baseline and after 4, 8, 12 and 16 weeks of treatment. At inclusion all patients had significantly (p < 0.001) elevated plasma IL-6, plasma VEGF and serum YKL-40 compared to healthy subjects. Eighteen patients responded to treatment (pooled data from both treatment groups), and they had significant (p < 0.05 to p < 0.001) decreases in plasma IL-6, plasma VEGF, serum YKL-40, ESR and DAS28 after 4 weeks of treatment and throughout the study (except serum YKL-40 at week 16). Plasma IL-6 showed the largest reductions. Non-responders had unchanged biomarkers. At week 16 the patients with DAS28 < 3.2 had lower levels compared to baseline values in plasma IL-6 (p = 0.005), plasma VEGF (p = 0.014), and ESR (p = 0.024).Plasma IL-6, plasma VEGF and serum YKL-40, which reflect different aspects of the inflammatory process, may provide useful information regarding early differentiation of responders from non-responders.

Original language	English
Journal	Biomarker Insights
Volume	4
Pages (from-to)	91-5
Number of pages	4
ISSN	1177-2719
Publication status	Published - 2009

Access to Document

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2796864/

Cite this

Knudsen, L. S., Hetland, M. L., Johansen, J. S., Skjødt, H., Peters, N. D., Colic, A., Grau, K., Nielsen, H. J., Østergaard, M., Knudsen, L. S., Hetland, M. L., Johansen, J. S., Skjødt, H., Peters, N. D., Colic, A., Grau, K., Nielsen, H. J., & Ostergaard, M. (2009). Changes in plasma IL-6, plasma VEGF and serum YKL-40 during Treatment with Etanercept and Methotrexate or Etanercept alone in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy. Biomarker Insights, 4, 91-5. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2796864/

Changes in plasma IL-6, plasma VEGF and serum YKL-40 during Treatment with Etanercept and Methotrexate or Etanercept alone in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy. / Knudsen, Lene Surland ; Hetland, Merete Lund ; Johansen, Julia Sidenius et al.
In: Biomarker Insights, Vol. 4, 2009, p. 91-5.

Research output: Contribution to journal › Journal article › Research › peer-review

Knudsen, LS , Hetland, ML , Johansen, JS, Skjødt, H, Peters, ND, Colic, A, Grau, K, Nielsen, HJ, Østergaard, M, Knudsen, LS, Hetland, ML, Johansen, JS, Skjødt, H, Peters, ND, Colic, A, Grau, K, Nielsen, HJ & Ostergaard, M 2009, 'Changes in plasma IL-6, plasma VEGF and serum YKL-40 during Treatment with Etanercept and Methotrexate or Etanercept alone in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy', Biomarker Insights, vol. 4, pp. 91-5. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2796864/>

@article{3d788200835911df928f000ea68e967b,

title = "Changes in plasma IL-6, plasma VEGF and serum YKL-40 during Treatment with Etanercept and Methotrexate or Etanercept alone in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy",

abstract = "Changes in plasma IL-6, plasma VEGF and serum YKL-40 were determined in rheumatoid arthritis (RA) patients during treatment with etanercept alone or in combination with methotrexate. Twenty-five patients with active RA (DAS28 >/= 3.2) were randomized to receive etanercept (25 mg sc. biweekly) plus methotrexate (n = 12) or etanercept alone (n = 13). Plasma IL-6, plasma VEGF and serum YKL-40 were determined by ELISA. The 3 biomarkers and DAS28 scores were evaluated at baseline and after 4, 8, 12 and 16 weeks of treatment. At inclusion all patients had significantly (p < 0.001) elevated plasma IL-6, plasma VEGF and serum YKL-40 compared to healthy subjects. Eighteen patients responded to treatment (pooled data from both treatment groups), and they had significant (p < 0.05 to p < 0.001) decreases in plasma IL-6, plasma VEGF, serum YKL-40, ESR and DAS28 after 4 weeks of treatment and throughout the study (except serum YKL-40 at week 16). Plasma IL-6 showed the largest reductions. Non-responders had unchanged biomarkers. At week 16 the patients with DAS28 < 3.2 had lower levels compared to baseline values in plasma IL-6 (p = 0.005), plasma VEGF (p = 0.014), and ESR (p = 0.024).Plasma IL-6, plasma VEGF and serum YKL-40, which reflect different aspects of the inflammatory process, may provide useful information regarding early differentiation of responders from non-responders.",

author = "Knudsen, {Lene Surland} and Hetland, {Merete Lund} and Johansen, {Julia Sidenius} and Henrik Skj{\o}dt and Peters, {Niels Daugaard} and Ada Colic and Karin Grau and Nielsen, {Hans J{\o}rgen} and Mikkel {\O}stergaard and Knudsen, {Lene Surland} and Hetland, {Merete Lund} and Johansen, {Julia Sidenius} and Henrik Skj{\o}dt and Peters, {Niels Daugaard} and Ada Colic and Karin Grau and Nielsen, {Hans J{\o}rgen} and Mikkel Ostergaard",

year = "2009",

language = "English",

volume = "4",

pages = "91--5",

journal = "Biomarker Insights",

issn = "1177-2719",

publisher = "Libertas Academica Ltd.",

}

TY - JOUR

T1 - Changes in plasma IL-6, plasma VEGF and serum YKL-40 during Treatment with Etanercept and Methotrexate or Etanercept alone in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy

AU - Knudsen, Lene Surland

AU - Hetland, Merete Lund

AU - Johansen, Julia Sidenius

AU - Skjødt, Henrik

AU - Peters, Niels Daugaard

AU - Colic, Ada

AU - Grau, Karin

AU - Nielsen, Hans Jørgen

AU - Østergaard, Mikkel

AU - Knudsen, Lene Surland

AU - Hetland, Merete Lund

AU - Johansen, Julia Sidenius

AU - Skjødt, Henrik

AU - Peters, Niels Daugaard

AU - Colic, Ada

AU - Grau, Karin

AU - Nielsen, Hans Jørgen

AU - Ostergaard, Mikkel

PY - 2009

Y1 - 2009

N2 - Changes in plasma IL-6, plasma VEGF and serum YKL-40 were determined in rheumatoid arthritis (RA) patients during treatment with etanercept alone or in combination with methotrexate. Twenty-five patients with active RA (DAS28 >/= 3.2) were randomized to receive etanercept (25 mg sc. biweekly) plus methotrexate (n = 12) or etanercept alone (n = 13). Plasma IL-6, plasma VEGF and serum YKL-40 were determined by ELISA. The 3 biomarkers and DAS28 scores were evaluated at baseline and after 4, 8, 12 and 16 weeks of treatment. At inclusion all patients had significantly (p < 0.001) elevated plasma IL-6, plasma VEGF and serum YKL-40 compared to healthy subjects. Eighteen patients responded to treatment (pooled data from both treatment groups), and they had significant (p < 0.05 to p < 0.001) decreases in plasma IL-6, plasma VEGF, serum YKL-40, ESR and DAS28 after 4 weeks of treatment and throughout the study (except serum YKL-40 at week 16). Plasma IL-6 showed the largest reductions. Non-responders had unchanged biomarkers. At week 16 the patients with DAS28 < 3.2 had lower levels compared to baseline values in plasma IL-6 (p = 0.005), plasma VEGF (p = 0.014), and ESR (p = 0.024).Plasma IL-6, plasma VEGF and serum YKL-40, which reflect different aspects of the inflammatory process, may provide useful information regarding early differentiation of responders from non-responders.

AB - Changes in plasma IL-6, plasma VEGF and serum YKL-40 were determined in rheumatoid arthritis (RA) patients during treatment with etanercept alone or in combination with methotrexate. Twenty-five patients with active RA (DAS28 >/= 3.2) were randomized to receive etanercept (25 mg sc. biweekly) plus methotrexate (n = 12) or etanercept alone (n = 13). Plasma IL-6, plasma VEGF and serum YKL-40 were determined by ELISA. The 3 biomarkers and DAS28 scores were evaluated at baseline and after 4, 8, 12 and 16 weeks of treatment. At inclusion all patients had significantly (p < 0.001) elevated plasma IL-6, plasma VEGF and serum YKL-40 compared to healthy subjects. Eighteen patients responded to treatment (pooled data from both treatment groups), and they had significant (p < 0.05 to p < 0.001) decreases in plasma IL-6, plasma VEGF, serum YKL-40, ESR and DAS28 after 4 weeks of treatment and throughout the study (except serum YKL-40 at week 16). Plasma IL-6 showed the largest reductions. Non-responders had unchanged biomarkers. At week 16 the patients with DAS28 < 3.2 had lower levels compared to baseline values in plasma IL-6 (p = 0.005), plasma VEGF (p = 0.014), and ESR (p = 0.024).Plasma IL-6, plasma VEGF and serum YKL-40, which reflect different aspects of the inflammatory process, may provide useful information regarding early differentiation of responders from non-responders.

M3 - Journal article

SN - 1177-2719

VL - 4

SP - 91

EP - 95

JO - Biomarker Insights

JF - Biomarker Insights

ER -

Changes in plasma IL-6, plasma VEGF and serum YKL-40 during Treatment with Etanercept and Methotrexate or Etanercept alone in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy

Abstract

Access to Document

Fingerprint

Cite this